Citations

Clear

1727 citation(s) found for "Fu, Alan".

Weighing the Social and Ethical Considerations of Maternal-Fetal Surgery
Antiel, Ryan M. , Flake, Alan W. , Collura, Christopher A. , Rintoul, Natalie E. , Lantos, John D. , Curlin, Farr A. , Tilburt, Jon C. , Brown, Stephen D. , Johnson, Mark Paul , Feudtner, Chris

Mayo Clinic

Pediatrics | November 3, 2017 | Volume: 140 | Issue: 6 | Pages: No page available

10.1542/peds.2017-0608 | PMID 29101225 Get It

OBJECTIVES: The ethics of maternal-fetal surgery involves weighing the importance of potential benefits, risks, and other consequences involving the pregnant woman, fetus, and other family members. We assessed clinicians’ ratings of the importance of 9 considerations relevant to maternal-fetal surgery. METHODS: This study was a discrete choice experiment contained within a 2015 national mail-based survey of 1200 neonatologists, pediatric surgeons, and maternal-fetal medicine physicians, with latent class analysis subsequently used to identify groups of physicians with similar ratings. RESULTS: Of 1176 eligible participants, 660 (56%) completed the discrete choice experiment. The highest-ranked consideration was of neonatal benefits, which was followed by consideration of the risk of maternal complications. By using latent class analysis, we identified 4 attitudinal groups with similar patterns of prioritization: “fetocentric” (n = 232), risk-sensitive (n = 197), maternal autonomy (n = 167), and family impact and social support (n = 64). Neonatologists were more likely to be in the fetocentric group, whereas surgeons were more likely to be in the risk-sensitive group, and maternal-fetal medicine physicians made up the largest percentage of the family impact and social support group. CONCLUSIONS: Physicians vary in how they weigh the importance of social and ethical considerations regarding maternal-fetal surgery. Understanding these differences may help prevent or mitigate disagreements or tensions that may arise in the management of these patients.
NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanoma
McWilliams, Robert R. , Allred, Jacob B., Slostad, Jessica , Katipamula, Rajini, Dronca, Roxana , Rumilla, Kandelaria M., Erickson, Lori A. , Bryce, Alan H. , Kottschade, Lisa A. , King, David M. , Leitch, John M., Slostad, Jessica A, Dronca, Roxana S., Bryce, Alan H , McWilliams, Robert R , Joseph, Richard W. , Markovic, Svetomir N. , Erickson, Lori A

Mayo Clinic

Cancer | October 17, 2017 | Volume: 124 | Issue: 3 | Pages: 537-545

10.1002/cncr.31072 | PMID 29044496 Get It

BACKGROUNDDespite the success of immune checkpoint and targeted therapy, many patients with melanoma ultimately require further treatment. The combination of carboplatin, paclitaxel, and bevacizumab (CPB) has demonstrated promising activity in a single‐arm study. In the current study, the authors performed a randomized phase 2 study to confirm efficacy and to determine whether adding everolimus would increase the activity of the combination.METHODSThrough the North Central Cancer Treatment Group, a total of 149 patients with unresectable AJCC 6th edition stage IV melanoma were randomized from May 2010 to May 2014 to either CPB or CPB with everolimus (CPBE). The primary endpoint was progression‐free survival (PFS), with secondary endpoints of overall survival (OS), response rate, and tolerability.RESULTSThe CPB and CPBE treatment arms were balanced with regard to age (median age: 59 years vs 58 years) and high lactate dehydrogenase (48% vs 51%), but were unbalanced with regard to sex (male sex: 72% vs 55%; P = .03). Overall, there was no difference noted with regard to PFS, with a median PFS of 5.6 months for CPB versus 5.1 months for CPBE (hazard ratio [HR], 1.14; 95% confidence interval [95% CI], 0.81‐1.62 [P = .44]), or for OS, with a median OS of 14.5 months for CPB versus 10.8 months for CPBE (HR, 1.16; 95% CI, 0.84‐1.84). The confirmed response rate was 13% for CPB and 23% for CPBE (P = .13). Toxicity was higher for CPBE compared with CPB (83% for grade 3 + and 14% for grade 4 + vs 63% for grade 3 + and 11% for grade 4+, respectively) (toxicities were graded using the Cancer Therapy Evaluation Program of the National Cancer Institute Common Terminology Criteria for Adverse Events [version 4.0]). Common grade 3 + toxicities were neutropenia, leukopenia, and fatigue, which occurred in both treatment arms with comparable frequency.CONCLUSIONSBoth experimental arms demonstrated activity, with a PFS of >5 months. However, the addition of everolimus to CPB failed to improve outcomes, with increased toxicity noted. These findings replicate the moderate antitumor activity of CPB, with future development possibly in combination with targeted or immunotherapy. Cancer 2018;124:537‐45. © 2017 American Cancer Society.
Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence
Kottke, Tim , Evgin, Laura , Shim, Kevin G. , Rommelfanger, Diana M., Boisgerault, Nicolas , Zaidi, Shane, Díaz, Rosa María, Thompson, Jill , Ilett, Elizabeth J. , Selby, Peter J. , Pandha, Hardev , Harrington, Kevin J. , Melcher, Alan , Vile, Richard G. , Rommelfanger, Diana, Ilett, Elizabeth J , Melcher, Alan A , Shim, Kevin G , Harrington, Kevin , Coffey, Matt C.

Mayo Clinic

Cancer Immunology Research | October 17, 2017 | Volume: 5 | Issue: 11 | Pages: 1029-1045

10.1158/2326-6066.cir-17-0175 | PMID 29038298 Get It

AbstractUnderstanding how incompletely cleared primary tumors transition from minimal residual disease (MRD) into treatment-resistant, immune-invisible recurrences has major clinical significance. We show here that this transition is mediated through the subversion of two key elements of innate immunosurveillance. In the first, the role of TNFα changes from an antitumor effector against primary tumors into a growth promoter for MRD. Second, whereas primary tumors induced a natural killer (NK)–mediated cytokine response characterized by low IL6 and elevated IFNγ, PD-L1hi MRD cells promoted the secretion of IL6 but minimal IFNγ, inhibiting both NK-cell and T-cell surveillance. Tumor recurrence was promoted by trauma- or infection-like stimuli inducing VEGF and TNFα, which stimulated the growth of MRD tumors. Finally, therapies that blocked PD-1, TNFα, or NK cells delayed or prevented recurrence. These data show how innate immunosurveillance mechanisms, which control infection and growth of primary tumors, are exploited by recurrent, competent tumors and identify therapeutic targets in patients with MRD known to be at high risk of relapse. Cancer Immunol Res; 5(11); 1029–45. ©2017 AACR.
Influence of metabolic syndrome and race on the relationship between intensive blood pressure control and cardiovascular outcomes in the SPRINT cohort
Dungan, Kathleen , Craven, Timothy E. , Soe, Kyaw , Wright, Jackson T. , Basile, Jan , Haley, William E. , Kressin, Nancy R. , Rani, Uzma , Tamariz, Leonardo , Whittle, Jeff , Wiggers, Alan , Osei, Kwame

Mayo Clinic

Diabetes, Obesity and Metabolism | October 12, 2017 | Volume: 20 | Issue: 3 | Pages: 629-637

10.1111/dom.13127 | PMID 29024310 Get It

Aims To determine whether baseline metabolic syndrome (MetS) modifies the effect of intensive blood pressure control on cardiovascular (CV) outcomes, and whether the effects varied by race/ethnicity. Methods We performed post hoc analyses among non‐Hispanic black, non‐hispanic white and Hispanic participants, with and without MetS, in the Systolic Blood Pressure Intervention Trial (SPRINT), who were randomized to a systolic blood pressure (SBP) target of <120 mm Hg (intensive group, N = 4544) or an SBP target of <140 mm Hg (standard group, N = 4553). The median follow‐up was 3.26 years. The primary outcome was the composite of the first occurrence of myocardial infarction, stroke, heart failure, non‐myocardial infarction acute coronary syndrome or CV death. Results Overall, 3521/9097 participants (38.7%) met the criteria for MetS at baseline. Baseline characteristics were similar in the two SBP target groups within each MetS subgroup, except body mass index was slightly higher in the standard arm of the MetS subgroup (33.3 ± 5.6 vs 33.0 ± 5.3 kg/m 2 ; P < .01), but were similar across treatment arms in the non‐MetS subgroup. The hazard ratio for the primary outcome was similarly reduced in participants with or without baseline MetS: 0.75 (95% confidence interval [CI] 0.57, 0.96) and 0.71 (95% CI 0.57, 0.87), respectively (adjusted P value for treatment by subgroup interaction = .98). Similarly, there was no evidence of treatment × MetS subgroup interaction for all‐cause mortality (adjusted interaction P value = .98). The findings were also similar across race/ethnic subgroups. Conclusions In this analysis the CV benefit of intensive SBP control did not differ among participants by baseline MetS status, regardless of race/ethnicity.
60 Utility of t wave amplitude as a non-invasive risk marker of sudden cardiac death in hypertrophic cardiomyopathy
Sugrue, Alan , Killu, AM, DeSimone, CV, Chahal, C. Anwar A. , Vogt, J. J., Křemen, Václav , Hai, Jo Jo , Hodge, DO, Acker, NG, Geske, JB, Ackerman, M. J., Ommen, SR, Noseworthy, PA, Brady, PA, Geske, Jeffrey B. , Chahal, Choudhary Anwar A , Kremen, Vaclav , Geske, Jeffrey B , Killu, Ammar M. , Desimone, C, Lin, Gen‐Min , Brady, PA

Mayo Clinic

Moderated poster session 3 | October 11, 2017 | Volume: No volume available | Issue: No issue available | Pages: A35-A36

10.1136/heartjnl-2017-ics17.59 Get It

Dendriform Pulmonary Ossification in the Absence of Usual Interstitial Pneumonia: CT Features and Possible Association With Recurrent Acid Aspiration
Gruden, James F. , Green, Daniel B. , Legasto, Alan C. , Jensen, Eric A., Panse, Prasad M.

Mayo Clinic

American Journal of Roentgenology | October 5, 2017 | Volume: 209 | Issue: 6 | Pages: 1209-1215

10.2214/ajr.17.18063 | PMID 28981359 Get It

Contemporary Primary Prevention Aspirin Use by Cardiovascular Disease Risk: Impact of US Preventive Services Task Force Recommendations, 2007—2015: A Serial, Cross‐sectional Study
Hof, Jeremy Van’t , Duval, Sue , Walts, Adrienne, Kopecky, Stephen L. , Luepker, Russell V. , Hirsch, Alan T.

Mayo Clinic

Journal of the American Heart Association | October 4, 2017 | Volume: 6 | Issue: 10 | Pages: No page available

10.1161/jaha.117.006328 | PMID 28974502 Get It

Background No previous study has evaluated the impact of past US Preventive Services Task Force statements on primary prevention ( PP ) aspirin use in a primary care setting. The aim of this study was to evaluate temporal changes in PP aspirin use in a primary care population, stratifying patients by their 10‐year global cardiovascular disease risk, in response to the 2009 statement. Methods and Results This study estimated biannual aspirin use prevalence using electronic health record data from primary care clinics within the Fairview Health System (Minnesota) from 2007 to 2015. A total of 94 270 patient encounters had complete data to estimate a 10‐year cardiovascular disease risk score using the 2013 American College of Cardiology/American Heart Association global risk estimator. Patients were stratified into low‐ (<10%), intermediate‐ (10–20%), and high‐ (≥20%) risk groups. Over the 9‐year period, PP aspirin use averaged 43%. When stratified by low, intermediate and high risk, average PP aspirin use was 41%, 63%, and 73%, respectively. Average PP aspirin use decreased after the publication of the 2009 US Preventive Services Task Force recommendation statement: from 45% to 40% in the low‐risk group; from 66% to 62% in the intermediate‐risk group; and from 76% to 73% in the high‐risk group, before and after the guideline. Conclusions Publication of the 2009 US Preventive Services Task Force recommendation was not associated with an increase in aspirin use. High risk PP patients utilized aspirin at high rates. Patients at intermediate risk were less intensively treated, and patients at low risk used aspirin at relatively high rates. These data may inform future aspirin guideline dissemination.
Interhospital Transfer Before Thrombectomy Is Associated With Delayed Treatment and Worse Outcome in the STRATIS Registry (Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke)
Froehler, Michael T. , Zaidat, Osama O., Aziz‐Sultan, Mohammad Ali , Klucznik, Richard , Hellinger, Frank R, Yavagal, Dileep R. , Yao, Tom L., Liebeskind, David S, Jadhav, Ashutosh P. , Gupta, Rishi , Hassan, Ameer E , Martin, Coleman, Bozorgchami, Hormozd, Kaushal, Ritesh , Gandhi, Ravi H. , Peterson, Eric C. , Given, Curtis A., Mehta, Brijesh , Deshmukh, Vivek R., Starkman, Sidney , Linfante, Italo , McPherson, Scott H., Kvamme, Peter , Grobelny, Thomas, Hussain, Muhammad Shazam , Thacker, Ike, Vora, Nirav , Monteith, Stephen J., Ecker, Robert D., Schirmer, Clemens M. , Sauvageau, Eric , Abou‐Chebl, Alex, Derdeyn, Colin P. , Maidan, Lucian, Badruddin, Aamir , Siddiqui, Adnan H. , Dumont, Travis M., Alhajeri, Abdulnasser, Taqi, Muhammad , Asi, Khaled, Carpenter, Jeffrey , Boulos, Alan S. , Jindal, Gaurav , Puri, Ajit S , Robinson, David , Kallmes, David F. , Baxter, Blaise, Jumaa, Mouhammad , Sunenshine, Peter, Majjhoo, Aniel, English, Joey , Fessler, Richard D., Martin, Jerry C., Mueller‐Kronast, Nils , Liebeskind, David S. , Liebeskind, David S. , Siddiqui, Adnan H , Hassan, Ameer E , Schirmer, Clemens M , Saver, Jeffrey L. , Jahan, Reza , Haussen, Diogo C , Nogueira, Raul G. , Dashti, Shervin R , Chen, Peng R , Chitale, Rohan V , Deshaies, Eric Michael , Suzuki, Shuichi , Almandoz, Josser E Delgado , Jadhav, Ashutosh P , Derdeyn, Colin P

Mayo Clinic

Circulation | September 25, 2017 | Volume: 136 | Issue: 24 | Pages: 2311-2321

10.1161/circulationaha.117.028920 | PMID 28943516 Get It

Background: Endovascular treatment with mechanical thrombectomy (MT) is beneficial for patients with acute stroke suffering a large-vessel occlusion, although treatment efficacy is highly time-dependent. We hypothesized that interhospital transfer to endovascular-capable centers would result in treatment delays and worse clinical outcomes compared with direct presentation. Methods: STRATIS (Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke) was a prospective, multicenter, observational, single-arm study of real-world MT for acute stroke because of anterior-circulation large-vessel occlusion performed at 55 sites over 2 years, including 1000 patients with severe stroke and treated within 8 hours. Patients underwent MT with or without intravenous tissue plasminogen activator and were admitted to endovascular-capable centers via either interhospital transfer or direct presentation. The primary clinical outcome was functional independence (modified Rankin Score 0–2) at 90 days. We assessed (1) real-world time metrics of stroke care delivery, (2) outcome differences between direct and transfer patients undergoing MT, and (3) the potential impact of local hospital bypass. Results: A total of 984 patients were analyzed. Median onset-to-revascularization time was 202.0 minutes for direct versus 311.5 minutes for transfer patients ( P <0.001). Clinical outcomes were better in the direct group, with 60.0% (299/498) achieving functional independence compared with 52.2% (213/408) in the transfer group (odds ratio, 1.38; 95% confidence interval, 1.06–1.79; P =0.02). Likewise, excellent outcome (modified Rankin Score 0–1) was achieved in 47.4% (236/498) of direct patients versus 38.0% (155/408) of transfer patients (odds ratio, 1.47; 95% confidence interval, 1.13–1.92; P =0.005). Mortality did not differ between the 2 groups (15.1% for direct, 13.7% for transfer; P =0.55). Intravenous tissue plasminogen activator did not impact outcomes. Hypothetical bypass modeling for all transferred patients suggested that intravenous tissue plasminogen activator would be delayed by 12 minutes, but MT would be performed 91 minutes sooner if patients were routed directly to endovascular-capable centers. If bypass is limited to a 20-mile radius from onset, then intravenous tissue plasminogen activator would be delayed by 7 minutes and MT performed 94 minutes earlier. Conclusions: In this large, real-world study, interhospital transfer was associated with significant treatment delays and lower chance of good outcome. Strategies to facilitate more rapid identification of large-vessel occlusion and direct routing to endovascular-capable centers for patients with severe stroke may improve outcomes. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02239640.
Circulating CD34+ Cell Count is Associated with Extent of Subclinical Atherosclerosis in Asymptomatic Amish Men, Independent of 10-Year Framingham Risk
Bielak, Lawrence F. , Horenstein, Richard B., Sheedy, Patrick F. , Rumberger, John A. , Tanner, Keith, Peyser, Patricia A. , Ryan, Kathleen A. , Post, Wendy S. , Mitchell, Braxton D. , Shuldiner, Alan R.

Mayo Clinic

Clinical medicine. Cardiology | September 20, 2017 | Volume: 3 | Issue: No issue available | Pages: CMC.S2111

10.4137/cmc.s2111 | PMID 20407620 Get It

Background Bone-marrow derived progenitor cells (PCs) may play a role in maintaining vascular health by actively repairing damaged endothelium. The purpose of this study in asymptomatic Old Order Amish men (n = 90) without hypertension or diabetes was to determine if PC count, as determined by CD34+ cell count in peripheral blood, was associated with 10-year risk of cardiovascular disease (CVD) and measures of subclinical atherosclerosis. Methods and Results CD34+ cell count by fluorescence-activated cell sorting, coronary artery calcification (CAC) by electron beam computed tomography, and CVD risk factors were obtained. Carotid intimal-medial thickness (CIMT) also was obtained in a subset of 57 men. After adjusting for 10-year CVD risk, CD34+ cell count was significantly associated with CAC quantity ( p =0.03) and CIMT ( p < 0.0001). A 1-unit increase in natural-log transformed CD34+ cell count was associated with an estimated 55.2% decrease (95% CI: −77.8% to −9.3%) in CAC quantity and an estimated 14.3% decrease (95% CI: −20.1% to −8.1%) in CIMT. Conclusions Increased CD34+ cell count was associated with a decrease in extent of subclinical atherosclerosis in multiple arterial beds, independent of 10-year CVD risk. Further investigations of associations of CD34+ cell count with subclinical atherosclerosis in asymptomatic individuals could provide mechanistic insights into the atherosclerotic process.
Association of midlife lipids with 20‐year cognitive change: A cohort study
Sharrett, A. Richey, Bandeen‐Roche, Karen , Ballantyne, Christie M. , Pokharel, Yashashwi , Michos, Erin D. , Penman, Alan D. , Ballantyne, Christie M , Michos, Erin D , Power, Melinda C. , Rawlings, Andreea M. , Coresh, Josef , Alonso, Álvaro , Knopman, David S. , Mosley, Thomas H. , Gottesman, Rebecca F.

Mayo Clinic

Alzheimer's & Dementia | September 12, 2017 | Volume: 14 | Issue: 2 | Pages: 167-177

10.1016/j.jalz.2017.07.757 | PMID 28916238 Get It

AbstractIntroductionExisting studies predominantly consider the association of late‐life lipid levels and subsequent cognitive change. However, midlife rather than late‐life risk factors are often most relevant to cognitive health.MethodsWe quantified the association between measured serum lipids in midlife and subsequent 20‐year change in performance on three cognitive tests in 13,997 participants of the Atherosclerosis Risk in Communities study.ResultsElevated total cholesterol, low‐density lipoprotein cholesterol, and triglycerides were associated with greater 20‐year decline on a test of executive function, sustained attention, and processing speed. Higher total cholesterol and triglycerides were also associated with greater 20‐year decline in memory scores and a measure summarizing performance on all three tests. High‐density lipoprotein cholesterol was not associated with cognitive change. Results were materially unchanged in sensitivity analyses addressing informative missingness.DiscussionElevated total cholesterol, low‐density lipoprotein cholesterol, and triglycerides in midlife were associated with greater 20‐year cognitive decline.